The University of Nottingham has partnered with Ximbio (www.ximbio.com), a subsidiary of Cancer Research UK, to make the University’s life science research tools more widely available to the worldwide scientific community.
Ximbio has been set up as an online portal for the life science community to change the way that reagents and other research tools are searched, sourced and shared. The portal aims to broaden the range of research tools, which are made available to scientists around the world in order to support and advance life science research.
Under the terms of the agreement, researchers from The University of Nottingham are able to add research tools and reagents to the Ximbio platform. The first researcher from the University to participate is Associate Professor, Rupert Fray, who has contributed a monoclonal antibody raised against N6-methyladenosine, a particularly exciting target.
For scientists looking for specific reagents to use in their experiments, Ximbio offers a fully searchable database, extensive datasheets, and supplier options, and in future will also feature peer reviews of listed products. Each reagent record can be linked to the originating inventor, enabling scientists and institutions to be credited for their work. Ximbio will operate as a business unit and will focus on all areas of biology.
Melanie Hardman, Head of Ximbio said: “We have created Ximbio to be a place where scientists can share their research, and reagent companies can source new products, in a streamlined process that saves both time and resource. We hope to accelerate life science research.”
Speaking about the partnership with Ximbio, Dr Susan Huxtable, Director of Intellectual Property and Commercialisation at The University of Nottingham, said: “This University already has an excellent long term relationship with Cancer Research UK and we are delighted to participate in this exciting new initiative with Ximbio. It provides a further platform to allow University of Nottingham researchers to contribute to the fight against cancer and to progress life-science research more widely.”
View the University of Nottingham's portfolio so far.